Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07258173 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety of a Single Dose of Emodepside Compared to a Single Dose of Albendazole in Adolescents and Adults Infected With Trichuris Incognita

Study acronym: EMOTI
StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 4 months later Sep 15, 2026 → Jan 15, 2027
See other at-risk trials from Jennifer Keiser

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: May 15, 2026 to Nov 15, 2026
    • Primary completion pushed from Sep 15, 2026 to Jan 15, 2027
    • Study completion pushed from Sep 15, 2026 to Feb 15, 2027
    v3
  2. Start date: Jan 15, 2026 to May 15, 2026
    • Primary and study completion dates: May 15, 2026 to Sep 15, 2026
    • Eligibility criteria revised
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this clinical trial is to compare the efficacy and safety of emodepside with the standard treatment, albendazole, in adolescents (12 years and older) and adults infected with Trichuris incognita.
Trial Details
NCT Number NCT07258173
Lead Sponsor Jennifer Keiser
Collaborators: Centre Suisse de Recherches Scientifiques en Cote d'Ivoire, Université Félix Houphouët-Boigny, Bayer
Conditions
(from sponsor)		 Trichuris Infection
Related terms Trichuriasis
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov